Quarterly ResultAug 4, 2026, 04:10 PM
Pacira BioSciences Q2 Revenue $192.4M, Up 6%; Divests iovera° Business
AI Summary
Pacira BioSciences reported solid second quarter 2026 financial results, with total revenue increasing 6% year-over-year to $192.4 million and GAAP net income of $4.7 million. The company also highlighted the recent divestiture of its iovera° business to Zimmer Biomet for up to $140 million, which closed on July 31, 2026. Key business advancements include expanded reimbursement for EXPAREL by UnitedHealthcare and progress in the PCRX-201 development program. Full-year 2026 total revenue guidance was updated to $735 million to $760 million, reflecting the iovera° divestiture.
Key Highlights
- Divested iovera° business to Zimmer Biomet for up to $140M, receiving $73.6M cash upfront.
- Q2 2026 total revenue increased 6% year-over-year to $192.4M.
- Q2 2026 GAAP net income was $4.7M, or $0.12 per share.
- Q2 2026 non-GAAP diluted net income was $0.73 per share.
- EXPAREL net product sales grew 3% to $147.8M in Q2 2026.
- UnitedHealthcare now provides separate reimbursement for EXPAREL in outpatient settings.
- PCRX-201 development advanced, with Phase 2 ASCEND study enrollment underway for Part B.
- Updated 2026 total revenue guidance to $735M-$760M due to iovera° divestiture.
Price Impact
More from PCRX